XERS Stock Analysis: Xeris Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.429m USD | 12M Return: 76.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.5M
Qual. Beats: 0
Rev. Trend: 99.4%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is a commercial-stage biopharmaceutical company headquartered in Chicago, Illinois, and incorporated in 2005. The company focuses on developing and commercializing therapies for chronic endocrine and neurological diseases, operating within the specialty pharmaceuticals segment of the healthcare sector.
Its marketed portfolio includes Gvoke, a ready-to-use liquid-stable glucagon for severe hypoglycemia; Keveyis, indicated for primary periodic paralysis and its variants; and Recorlev, a cortisol synthesis inhibitor approved for endogenous hypercortisolemia in adult Cushings syndrome patients. These products are largely aimed at rare or underserved endocrine and neurological conditions, a common focus among small-cap specialty biopharma firms seeking differentiated, high-margin therapeutic niches.
Xeris is also advancing XP-8121, a once-weekly subcutaneous levothyroxine candidate currently in Phase 3 clinical development for hypothyroidism. As a small-cap pharmaceutical company that went public in June 2018, Xeris relies on a combination of product revenue, pipeline progression, and regulatory milestones to drive long-term value.
- Gvoke glucagon revenue growth accelerates year over year
- Recorlev uptake drives Cushings syndrome franchise expansion
- Cash burn raises dilution risk amid pipeline development spending
| Net Income: 12.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 20.74 > 1.0 |
| NWC/Revenue: 42.27% < 20% (prev 30.74%; Δ 11.53% < -1%) |
| CFO/TA 0.12 > 3% & CFO 48.5m > Net Income 12.0m |
| Net Debt (153.1m) to EBITDA (46.1m): 3.32 < 3 |
| Current Ratio: 2.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (177.6m) vs 12m ago 16.52% < -2% |
| Gross Margin: 81.59% > 18% (prev 80.99%; Δ 0.60% > 0.5%) |
| Asset Turnover: 89.01% > 50% (prev 70.55%; Δ 18.46% > 0%) |
| Interest Coverage Ratio: 1.17 > 6 (EBIT TTM 33.5m / Interest Expense TTM 28.7m) |
| A: 0.34 (Total Current Assets 251.7m - Total Current Liabilities 118.6m) / Total Assets 392.0m |
| B: -1.71 (Retained Earnings -669.1m / Total Assets 392.0m) |
| C: 0.09 (EBIT TTM 33.5m / Avg Total Assets 353.7m) |
| D: 0.03 (Book Value of Equity 13.0m / Total Liabilities 379.0m) |
| Altman-Z'' = -2.66 = D |
| DSRI: 0.86 (Receivables 56.3m/46.3m, Revenue 314.9m/222.6m) |
| GMI: 0.99 (GM 80.99% / 81.59%) |
| AQI: 0.73 (AQ_t 0.29 / AQ_t-1 0.39) |
| SGI: 1.41 (Revenue 314.9m / 222.6m) |
| TATA: -0.09 (NI 12.0m - CFO 48.5m) / TA 392.0m) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of July 06, 2026, the stock is trading at USD 8.28 with a total of 3,753,200 shares traded. Over the past week, the price has changed by +11.89%, over one month by +33.98%, over three months by +36.86% and over the past year by +76.17%.
Current recommended Stop Loss: 7.90 (which is 4.6% or 1.4 ATR below the current price).
Xeris Pharmaceuticals has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy XERS.
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11.3 | 36.4% |
P/E Trailing = 118.2857
P/E Forward = 100.0
P/S = 4.5401
P/B = 106.0851
Revenue TTM = 314.9m USD
EBIT TTM = 33.5m USD
EBITDA TTM = 46.1m USD
Long Term Debt = 221.2m USD (from longTermDebt, last quarter)
Short Term Debt = 6.27m USD (from shortTermDebt, last quarter)
Debt = 264.8m USD (corrected: LT Debt 221.2m + ST Debt 6.27m) + Leases 37.3m
Net Debt = 153.1m USD (calculated: Debt 264.8m - CCE 111.8m)
Enterprise Value = 1.58b USD (1.43b + Debt 264.8m - CCE 111.8m)
Interest Coverage Ratio = 1.17 (Ebit TTM 33.5m / Interest Expense TTM 28.7m)
EV/FCF = 33.51x (Enterprise Value 1.58b / FCF TTM 47.2m)
FCF Yield = 2.98% (FCF TTM 47.2m / Enterprise Value 1.58b)
FCF Margin = 15.00% (FCF TTM 47.2m / Revenue TTM 314.9m)
Net Margin = 3.81% (Net Income TTM 12.0m / Revenue TTM 314.9m)
Gross Margin = 81.59% ((Revenue TTM 314.9m - Cost of Revenue TTM 58.0m) / Revenue TTM)
Gross Margin QoQ = 84.02% (prev 77.77%)
Tobins Q-Ratio = 4.04 (Enterprise Value 1.58b / Total Assets 392.0m)
Interest Expense / Debt = 10.82% (Interest Expense 28.7m / Debt 264.8m)
Taxrate = 0.0% (0.0 / 12.0m)
NOPAT = 33.5m (EBIT 33.5m * (1 - 0.00%))
Current Ratio = 2.12 (Total Current Assets 251.7m / Total Current Liabilities 118.6m)
Debt / Equity = 20.35 (Debt 264.8m / totalStockholderEquity, last quarter 13.0m)
Debt / EBITDA = 3.32 (Net Debt 153.1m / EBITDA 46.1m)
Debt / FCF = 3.24 (Net Debt 153.1m / FCF TTM 47.2m)
Total Stockholder Equity = 1.63m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.39% (Net Income 12.0m / Total Assets 392.0m)
RoE = 735.0% (Net Income TTM 12.0m / Total Stockholder Equity 1.63m)
RoCE = 15.04% (EBIT 33.5m / Capital Employed (Equity 1.63m + L.T.Debt 221.2m))
RoIC = 12.70% (NOPAT 33.5m / Invested Capital 263.9m)
WACC = 9.78% (E(1.43b)/V(1.69b) * Re(9.59%) + D(264.8m)/V(1.69b) * Rd(10.82%) * (1-Tc(0.0)))
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 11.83%
[DCF] Terminal Value 70.58% ; FCFF base≈47.2m ; Y1≈47.4m ; Y5≈50.2m
[DCF] Fair Price = 2.75 (EV 628.2m - Net Debt 153.1m = Equity 475.1m / Shares 172.6m; r=9.78% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.81 | # QB: 0
Revenue Correlation: 99.38 | Revenue CAGR: 34.36% | SUE: 1.25 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=+25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.04 | Chg30d=-14.66% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=0.14 | Chg30d=+0.14% | Revisions=+17% | GrowthEPS=+0.0% | GrowthRev=+32.3%
EPS next Year (2027-12-31): EPS=0.40 | Chg30d=+6.61% | Revisions=+0% | GrowthEPS=+177.2% | GrowthRev=+22.5%
[Analyst] Revisions Ratio: +15% (up=6, down=4)